168 related articles for article (PubMed ID: 26028101)
21. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
22. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications.
Khan MA; Srivastava SK; Bhardwaj A; Singh S; Arora S; Zubair H; Carter JE; Singh AP
Oncotarget; 2015 Nov; 6(36):39140-50. PubMed ID: 25970774
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Hering J; Garrean S; Dekoj TR; Razzak A; Saied A; Trevino J; Babcock TA; Espat NJ
Ann Surg Oncol; 2007 Dec; 14(12):3620-8. PubMed ID: 17896154
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
26. Cure of gemcitabine-induced systemic capillary leak syndrome without corticosteroids.
Spanos S; Vourliotaki I; Drossitis I; Tsoussis S
J BUON; 2009; 14(4):728-9. PubMed ID: 20148474
[No Abstract] [Full Text] [Related]
27. Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines.
Park SH; Sung JH; Kim EJ; Chung N
Braz J Med Biol Res; 2015 Feb; 48(2):111-9. PubMed ID: 25517919
[TBL] [Abstract][Full Text] [Related]
28. Astragalus polysaccharides suppress ICAM-1 and VCAM-1 expression in TNF-α-treated human vascular endothelial cells by blocking NF-κB activation.
Zhu YP; Shen T; Lin YJ; Chen BD; Ruan Y; Cao Y; Qiao Y; Man Y; Wang S; Li J
Acta Pharmacol Sin; 2013 Aug; 34(8):1036-42. PubMed ID: 23728723
[TBL] [Abstract][Full Text] [Related]
29. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Guo Q; Chen Y; Wu Y
Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
[TBL] [Abstract][Full Text] [Related]
30. [Effects of monocyte chemotactic protein-3 on ICAM-1, VCAM-1, TF, and TFPI expression and apoptosis in human umbilical vein endothelial cells].
Chen J; Zhang B; Pan C; Ren L; Chen Y
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jan; 33(1):86-92. PubMed ID: 23353163
[TBL] [Abstract][Full Text] [Related]
31. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
32. Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells.
Jiang PH; Motoo Y; Sawabu N; Minamoto T
World J Gastroenterol; 2006 Mar; 12(10):1597-602. PubMed ID: 16570353
[TBL] [Abstract][Full Text] [Related]
33. Suppression of
Xing HB; Tong MT; Wang J; Hu H; Zhai CY; Huang CX; Li D
Biomed Res Int; 2018; 2018():3195025. PubMed ID: 29693005
[TBL] [Abstract][Full Text] [Related]
34. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Ng SSW ; Tsao MS; Chow S; Hedley DW
Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
[TBL] [Abstract][Full Text] [Related]
36. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
Simon PO; McDunn JE; Kashiwagi H; Chang K; Goedegebuure PS; Hotchkiss RS; Hawkins WG
Int J Cancer; 2009 Aug; 125(4):942-51. PubMed ID: 19405118
[TBL] [Abstract][Full Text] [Related]
37. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
38. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Tang ZY; Wu YL; Gao SL; Shen HW
J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
[TBL] [Abstract][Full Text] [Related]
39. Effect of liquiritigenin, a flavanone existed from Radix glycyrrhizae on pro-apoptotic in SMMC-7721 cells.
Zhang SP; Zhou YJ; Liu Y; Cai YQ
Food Chem Toxicol; 2009 Apr; 47(4):693-701. PubMed ID: 19150383
[TBL] [Abstract][Full Text] [Related]
40. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
